Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus.

Authors:
Doua F Azzouz
Doua F Azzouz
Centre Hospitalo-Universitaire de Nice
France
Gabriel V Martin
Gabriel V Martin
INSERM UMRs 1097
Fanny Arnoux
Fanny Arnoux
Aix Marseille Université
France
Nathalie Balandraud
Nathalie Balandraud
France; Laboratoire d'immunogénétique
Thierry Martin
Thierry Martin
Hôpitaux Universitaires de Strasbourg
France
Sylvain Dubucquoi
Sylvain Dubucquoi
Universite' Lille Nord de France;
France
Eric Hachulla
Eric Hachulla
Université Paris Descartes
France
Dominique Farge-Bancel
Dominique Farge-Bancel
Saint Louis Hospital
France

PLoS One 2016 12;11(9):e0160283. Epub 2016 Sep 12.

INSERM UMRs 1097, Parc Scientifique de Luminy, Marseille, France.

In a pilot ProtoArray analysis, we identified 6 proteins out of 9483 recognized by autoantibodies (AAb) from patients with systemic sclerosis (SSc). We further investigated the 6 candidates by ELISA on hundreds of controls and patients, including patients with Systemic Lupus Erythematosus (SLE), known for high sera reactivity and overlapping AAb with SSc. Only 2 of the 6 candidates, Ephrin type-B receptor 2 (EphB2) and Three prime Histone mRNA EXonuclease 1 (THEX1), remained significantly recognized by sera samples from SSc compared to controls (healthy or with rheumatic diseases) with, respectively, 34% versus 14% (P = 2.10-4) and 60% versus 28% (P = 3.10-8). Above all, EphB2 and THEX1 revealed to be mainly recognized by SLE sera samples with respectively 56%, (P = 2.10-10) and 82% (P = 5.10-13). As anti-EphB2 and anti-THEX1 AAb were found in both diseases, an epitope mapping was realized on each protein to refine SSc and SLE diagnosis. A 15-mer peptide from EphB2 allowed to identify 35% of SLE sera samples (N = 48) versus only 5% of any other sera samples (N = 157), including SSc sera samples. AAb titers were significantly higher in SLE sera (P<0.0001) and correlated with disease activity (p<0.02). We could not find an epitope on EphB2 protein for SSc neither on THEX1 for SSc or SLE. We showed that patients with SSc or SLE have AAb against EphB2, a protein involved in angiogenesis, and THEX1, a 3'-5' exoribonuclease involved in histone mRNA degradation. We have further identified a peptide from EphB2 as a specific and sensitive tool for SLE diagnosis.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160283PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019431PMC
August 2017
69 Reads
3.23 Impact Factor

Publication Analysis

Top Keywords

sera samples
20
sle sera
12
exonuclease thex1
8
mrna exonuclease
8
histone mrna
8
patients systemic
8
receptor ephb2
8
type-b receptor
8
prime histone
8
sera
7
samples
5
sle
5
ssc
5
210-4 60%
4
60% versus
4
14% 210-4
4
versus 14%
4
34% versus
4
revealed recognized
4
thex1 revealed
4

Altmetric Statistics

Similar Publications

Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.

J Rheumatol 2000 Jan;27(1):142-8

Department of Microbiology/Immunology, College of Medicine, University of Illinois at Chicago, USA.

Objective: To determine the disease sensitivity and specificity of testing for autoantibodies against 2 of the 3 main human centromere antigenic components, CENP-A and CENP-B (recombinant, expressed in baculovirus).

Methods: ELISA with CENP-A and CENP-B antigens were used to test 45 sera showing a centromere pattern by immunofluorescence (IFA) and sera from 96 patients with systemic sclerosis (SSc), subdivided into diffuse (dSSc) and limited (lSSc) forms. For controls, the same tests were performed on sera from 100 patients with rheumatoid arthritis (RA), 100 with systemic lupus erythematosus (SLE), and 50 random blood donors. Read More

View Article
January 2000

Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.

Int Immunol 2009 Apr 11;21(4):415-22. Epub 2009 Feb 11.

Department of Immunology and Rheumatology, University of Pécs, Pécs, Hungary.

Auto-antibodies against topoisomerase I (topo I) are frequently detected in sera of systemic sclerosis (SSc) patients. Anti-topo I auto-antibodies are considered to be associated with the diffuse cutaneous form of systemic sclerosis (dcSSc). However, anti-topo I auto-antibodies are also detected in limited cutaneous systemic sclerosis (lcSSc) and systemic lupus erythematosus (SLE). Read More

View Article
April 2009

Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.

Arthritis Rheum 2008 May;58(5):1226-36

Technical University Dresden, Dresden, Germany.

Objective: T cell intracytoplasmic antigen 1 (TIA-1) and TIA-1-related protein (TIAR) are involved in posttranscriptional regulation of the expression of tumor necrosis factor alpha (TNFalpha) and other proteins. Given the pivotal role of TNFalpha in chronic inflammatory diseases, this study was undertaken to analyze sera from patients with systemic autoimmune diseases for the presence of autoantibodies to TIA proteins and to investigate the expression of these proteins in inflamed tissue.

Methods: The presence of autoantibodies to TIA proteins in sera from 385 patients with rheumatic diseases and healthy controls was determined by immunoblotting using recombinant antigens. Read More

View Article
May 2008

Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis.

Arthritis Rheumatol 2015 Jul;67(7):1891-903

Università Politecnica delle Marche and Ospedali Riuniti Ancona, Ancona, Italy.

Objective: To identify the epitopes recognized by autoantibodies targeting platelet-derived growth factor receptor α (PDGFRα) in systemic sclerosis (SSc) and develop novel assays for detection of serum anti-PDGFRα autoantibodies.

Methods: Epstein-Barr virus-immortalized B cells from 1 patient with SSc (designated PAM) were screened for expression of IgG binding to PDGFRα and induction of reactive oxygen species in fibroblasts. The variable regions of anti-PDGFRα IgG were cloned into an IgG expression vector to generate distinct recombinant human monoclonal autoantibodies (mAb), which were characterized by binding and functional assays. Read More

View Article
July 2015